DDR1 and cancer: Since blocking DDRs kinase activity emerged as an attractive therapeutic option in cancer, inflammatory, and fibrotic diseases (Bansod et al., 2021; Denny and Flanagan, 2021; Elkamhawy et al., 2021; Dong et al., 2022), significant effort has been made to identify potent and selective DDR1 inhibitors.